Literature DB >> 25696331

Coexistence of a bradycardia- and tachycardia-dependent bundle branch block.

H M M Al Hashimi, A J J van Es, T Szili-Torok, M Gardien, G P Molhoek, P M J Verhorst.   

Abstract

Aberrant ventricular conduction is a rare phenomenon as compared with the more frequently occurring antrioventricular conduction disturbances. It leads to widening of the QRS complex, which is either due to a complete or functional block in one of the bundle branches or a block within the intramyocardial conduction system itself. Mechanisms that are potentially involved in the genesis of aberrant ventricular conduction are sudden shortening of cycle length (tachycardia-dependent phase III), antegrade block with retrograde concealed conduction, or bradycardia-dependent block (enhanced phase IV). In this paper, we present a patient with aberrant ventricular conduction with the occurrence of a tachycardia-dependent, as well as a bradycardia-dependent bundle branch block, which is an even rarer phenomenon.

Entities:  

Keywords:  bradycardia-dependent; bundle branch block; mechanism; tachycardia-dependent

Year:  2004        PMID: 25696331      PMCID: PMC2497117     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  4 in total

1.  An Address ON CERTAIN PHYSICAL SIGNS OF MYOCARDIAL INVOLVEMENT: Delivered at the Opening of the North-East London Post-Graduate College.

Authors:  T Lewis
Journal:  Br Med J       Date:  1913-03-08

2.  Bradycardia-dependent bundle branch block. Relation to supernormal conduction and phase 4 depolarization.

Authors:  N S Sarachek
Journal:  Am J Cardiol       Date:  1970-06       Impact factor: 2.778

3.  Aberrant conduction due to retrograde activation of the right bundle branch.

Authors:  R Parameswaran; R Monheit; H Goldberg
Journal:  J Electrocardiol       Date:  1970       Impact factor: 1.438

4.  Bradycardia-dependent bundle-branch block. A critique and proposed criteria.

Authors:  R A Massumi
Journal:  Circulation       Date:  1968-12       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.